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Abstract Xanthine oxidoreductase (XOR) catalyses the reduc-
tion of the therapeutic organic nitrate, nitroglycerin (glyceryl
trinitrate, GTN), as well as inorganic nitrate and nitrite, to nitric
oxide (NO) under hypoxic conditions in the presence of NADH.
Generation of nitric oxide is not detectable under normoxic
conditions and is inhibited by the molybdenum site-specific
inhibitors, oxypurinol and (3)BOF 4272. These enzymic
reactions provide a mechanism for generation of NO under
hypoxic conditions where nitric oxide synthase does not function,
suggesting a vasodilatory role in ischaemia.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Nitric oxide (NO) is widely recognised as mediating the
relaxation of smooth muscle in vasodilation and as initiating
many other important biological functions, including inhibi-
tion of platelet aggregation and adhesion [1,2]. Its generally
accepted physiological source is NO synthase [3], a complex
enzyme which is totally dependent on oxygen for its activity
and consequently ine¡ective in a hypoxic environment, where
the vasodilatory properties of NO might be seen to be advan-
tageous.
Organic nitrates have been used therapeutically for over 100
years in the treatment and prophylaxis of angina pectoris [4].
These drugs, which include glyceryl trinitrate (GTN) and iso-
sorbide dinitrate (ISDN), have a potent vasodilator activity,
the most likely mechanism for which is reduction to nitric
oxide in the endothelium and/or vascular smooth muscle [5].
The mechanisms by which organic nitrates are reduced in vivo
to NO have never been fully explained. Endogenous sulphy-
dryl groups have been implicated in the generation of S-nitro-
sothiols, which subsequently break down to produce NO [6,7].
Enzymic metabolism has also been proposed, involving gluta-
thione-S-transferases [8,9] or members of the cytochrome
P-450 family of enzymes [10,11]. On the other hand, evidence
has been presented showing that glutathione-S-transferases
are capable of reduction of nitrate to nitrite but not to NO
[12].
Xanthine oxidoreductase (XOR) is a complex molybdo£a-
voprotein, which has been studied as the essentially pure en-
zyme for almost 60 years [13]. In addition to molybdenum
and FAD, it contains two iron-sulphur redox centres and
has a wide substrate speci¢city, typically hydroxylating pu-
rines and concomitantly reducing either NAD (dehydrogen-
ase form, EC 1.1.1.204) or molecular oxygen (primarily the
oxidase form EC 1.1.3.22) [14]. The latter reaction generates
the reactive oxygen species, superoxide anion and hydrogen
peroxide, and it is this ability, with its implications for ischae-
mia-reperfusion injury, that has led to the enzyme’s becoming
a focus of research activity over the last two decades [15,16].
Much less well known is XOR’s capacity to reduce inorganic
nitrate to nitrite under conditions of low oxygen tension [17^
19]; a property that is perhaps not surprising in view of the
enzyme’s many similarities with the assimilatory nitrate reduc-
tases of fungi, algae and higher plants. Like XOR, the nitrate
reductases contain both molybdenum and FAD redox centres
and utilise NAD(P)H as reducing substrate [20].
We now report that, under hypoxic conditions and in the
presence of NADH, XOR is capable of catalysing the reduc-
tion of GTN, as well as inorganic nitrate and nitrite, to NO.
We believe that these ¢ndings, coupled with the vascular lo-
cation of the enzyme, suggest a role for XOR not only in the
metabolism of GTN but also as a source of NO derived from
endogenous nitrate and nitrite, under ischaemic conditions
ranging from sub-normoxia to anoxia when NO synthase
does not function.
2. Methods and materials
2.1. Materials
Bovine xanthine oxidase (1.4 U/mg) was obtained from Biozyme,
Blaenavon, UK. GTN (David Bull Laboratories, Warwick, UK), in
injectable form, was diluted in 100 mM potassium phosphate bu¡er,
pH 7.2, containing 0.9% NaCl (PPB) to give a stock concentration of
10 mM. Inorganic nitrate (KNO3) and nitrite (NaNO2) (Sigma, Poole,
UK) were treated in the same manner. NADH (Sigma) was diluted in
PPB to a stock concentration of 1 mM. Oxypurinol (Sigma) and
(3)BOF-4272 (Otsuka Pharmaceutical Factory, Japan) were made
up in PPB also at stock concentrations of 1 mM. All solutions were
freshly prepared on the day of use and maintained on ice until re-
quired.
2.2. Determination of nitric oxide
Nitric oxide determinations were made by using an ozone chemilu-
minescence assay in a continuous £ow apparatus (Sievers NOA 280)
that allows the real time analysis of NO production. The apparatus
was modi¢ed to allow a constant stream of nitrogen to £ow into the
reaction chamber. Chemiluminescence data were collected by a data
acquisition system; the mean NO produced in parts per billion (ppb)
was calculated from readings taken every second and shown as NO
ppb/s.
Progress curves, of molar production of NO against time, were
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calculated by taking into account the gas £ow and successively inte-
grating the ppb/s curves. Reactions were carried out in a ¢nal volume
of 1 ml at 37‡C in an atmosphere of 6 1% oxygen (Stathkelvin oxy-
gen electrode).
2.3. Determination of inhibition constants
In inhibition experiments, Ki values were determined by ¢tting to
the inhibition function i = I/I+C where I is the concentration of in-
hibitor, C is a constant and i = 1-vi/vo, in which vo = uninhibited rate,
vi = inhibited rate. Assuming competitive inhibition, C = Ki(1+S/Km).
Here S is the concentration of the competing substrate (GTN) and Km
is its Michaelis constant [21].
3. Results
3.1. XOR-catalysed reduction of GTN to NO
At low oxygen tension, NO is generated when XOR is in-
cubated in the presence of GTN and NADH. A typical rate
vs. time pro¢le is shown in Fig. 1, in which it can be seen that,
after a lag phase, a steady state rate (represented by the pla-
teau) is achieved. Fig. 1 also illustrates that introduction of air
abolished NO generation. Steady-state rates were shown to be
directly proportional to enzyme concentration. Generation of
NO was found to be dependent on each component of the
reaction mixture, without any one of which NO production
was not detectable. The reaction followed Michaelis-Menten
kinetics (Fig. 2) with apparent Km and Vmax values for GTN
of 0.33 þ 0.05 mM and 1.83 þ 0.08U1037 mol/min/mg, respec-
tively.
Substitution of xanthine for NADH as reducing substrate
under the above conditions gave no detectable NO produc-
tion. The molybdenum site-directed XOR inhibitors, oxypuri-
nol [22] and (3)BOF-4272 [23] inhibited, in a dose-dependent
manner, NO production catalysed by XOR in the presence of
GTN and NADH. Xanthine and, to a lesser extent, hypoxan-
thine similarly inhibited NO generation. Ki values determined
as described in the Section 2 are oxypurinol, 2.8U1037 M;
(3)BOF-4272, 3.2U1038 M; xanthine, 2.5U1037 M; hypo-
xanthine, 2.5U1036 M. Representative semilogarithmic plots
of relative rates vs. inhibitor concentration for (3)BOF-4272,
xanthine and oxypurinol are displayed in Fig. 3.
3.2. XOR-catalysed reduction of inorganic nitrate and nitrite
to NO
XOR catalysed the reduction of both inorganic nitrate and
nitrite to NO in the presence of NADH. Reduction of nitrate
followed Michaelis-Menten kinetics (Fig. 4), giving apparent
Km and Vmax values of 0.29 þ 0.6 mM and 9.7 þ 0.3U1038
mol/min/mg, respectively. In the case of nitrite reduction,
the data, ¢tted to a Michaelis-Menten hyperbola (Fig. 5, in-
set), gave operational apparent Km and Vmax values of
22.9 þ 8.1 mM and 3.73 þ 0.72U1036 mol/min/mg, respec-
tively. However, the Hanes-Woolf linear plot (Fig. 5) shows
systematic deviation from Michaelis-Menten kinetics.
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Fig. 1. Chemiluminescence data showing the time dependence of
rates of NO production (ppb/s) catalysed by XOR in the presence
of 3 mM GTN and 300 WM NADH in an atmosphere containing
6 1% oxygen. Solutions of GTN and NADH, in 100 mM potassium
phosphate bu¡er, pH 7.4, were mixed and purged with a continuous
stream of nitrogen over 5 min before addition (arrow) of a similarly
purged solution of XOR (1 U, 0.71 mg) in the same bu¡er. At the
time point indicated (arrow) the £ow of nitrogen was replaced by
air.
Fig. 2. Hanes-Woolf plot of NO production catalysed by XOR in
the presence of GTN and 300 WM NADH. Experimental conditions
are described in the legend to Fig. 1 for a given concentration of
GTN; progress curves were derived as outlined in Section 2. Inset
shows the Michaelis-Menten curve ¢tted to the data.
Fig. 3. Inhibition, by oxypurinol, (3)BOF-4272, and xanthine of
NO production catalysed by XOR in the presence of 3 mM GTN
and 300 WM NADH. Experimental conditions are described in the
legend to Fig. 1 except that inhibitor, at the appropriate concentra-
tion, was added immediately prior to addition of enzyme. Inhibi-
tions are displayed as semilogarithmic plots of percentage inhibition
vs. inhibitor concentration; vi is the inhibited rate and vo is the rate
in the absence of inhibitor. The solid lines are drawn using parame-
ters obtained from the ¢ts of inhibition data as described in Section
2. Error bars on experimental points represent þ S.E.M. of dupli-
cate determinations from each of two experiments.
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4. Discussion
We show that, under conditions of low oxygen tension,
XOR catalyses the reduction of the organic nitrate, GTN,
to NO in the presence of NADH.
The ability of NADH to act as a reducing substrate for
XOR has long been known [24] but has been little studied
and is not generally recognised. In air-saturated medium,
both dehydrogenase and oxidase forms of XOR show
NADH oxidase activity [25], generating superoxide anion
and hydrogen peroxide at maximal rates of NADH oxidation
of approximately 3U1037 mol/min/mg. This compares with a
maximal rate of 1.8U1037 mol NO/min/mg XOR determined
at 1% oxygen in the present studies. Considering a XOR con-
centration of 1034 mg/mg endothelial cell protein (Harrison,
unpublished data), this rate appoximates to 20 pmol NO/min/
mg cell XOR protein; a rate comparable with that determined
by Feelisch et al. [26] in endothelial cells exposed to GTN. In
view of the likely competition between GTN and molecular
oxygen for NADH-generated reducing equivalents on XOR, it
is to be expected that NO production will increase as oxygen
tension falls further. Conversely, it appears from our results
that, as normoxic conditions are approached, oxygen com-
petes increasingly for available electrons.
By analogy with the nitrate reductases [20] it might be an-
ticipated that GTN acts at the molybdenum site of XOR. This
is consistent with our demonstration of inhibition of NO pro-
duction by oxypurinol [22], (3)BOF-4272 [23]. It is well es-
tablished that NADH donates electrons and molecular oxygen
accepts electrons at the FAD site of XOR [14].
Regarding the pathway of NO production from GTN, the
present data are consistent with initial reduction to inorganic
nitrite, although determination of the latter by the commonly
used Griess reaction [27] was not feasible in the presence of
NADH as electron donor. Certainly, XOR was found readily
to catalyse the reduction of nitrite to NO. Rates were 30^50-
fold faster than those determined with GTN or inorganic
nitrate as reducing substrates, suggesting that reduction of
nitrate is the rate-limiting step in NO production in these
latter cases.
On the basis of these considerations, a plausible case can be
made for a role for XOR in metabolism of GTN and of other
organic nitrates in vivo (we also observed conversion of ISDN
to NO by XOR; data not shown). Endothelial cells have been
identi¢ed as a site of bioactivation of organic nitrates to NO
[27], a process deemed to be enzymically catalysed [27]. XOR
is known to be present at relatively high levels in endothelial
cells [28], in which its enzymic activity has been shown to be
increased in hypoxia [29,30]. Under conditions of ischaemia,
NADH levels will rise, and as oxygen tension falls NO gen-
eration will be increasingly favoured. It is relevant that organ-
ic nitrates are generally more e¡ective in the venous circula-
tion than in large coronary arteries or (still less e¡ective) in
arterioles [1,31], a comparison that re£ects the distribution of
XOR activity [32]. It is worth noting that hypoxanthine in-
hibits XOR-catalysed generation of NO, albeit less e¡ectively
than does xanthine. Concentrations of hypoxanthine are gen-
erally assumed to be elevated in ischaemia [33,34] and, de-
pending on the actual levels attained, rates of NO production
via this route could be a¡ected. However, hypoxanthine lev-
els, most commonly determined in complete ischaemia, are
uncertain under conditions of reduced blood £ow [34]. More-
over, rates of NO generation clearly depend upon oxygen
tension, itself subject to wide variation in the pathological
state. It is, accordingly, di⁄cult to predict the magnitude of
these e¡ects in vivo.
XOR-catalysed generation of NO under hypoxic conditions
can be seen as complementary to the activity of NO synthase,
which requires oxygen [3]. Thus, in ischaemic blood vessels,
XOR catalyses the metabolism of GTN to NO, which medi-
ates vasodilation and relief from angina. Under these hypoxic
conditions meanwhile, NO synthase is induced [35^37] and,
being dependent on molecular oxygen for its function, is set to
take over NO production as the oxygen tension rises and
XOR-catalysed NO production shuts down. This complemen-
tarity is also relevant in the absence of ingested organic ni-
trates, when circulating inorganic nitrates and/or nitrites could
act as oxidising substrates for XOR-catalysed generation of
NO under ischaemic conditions. Such a role for XOR would
be consistent with our ¢ndings and with those of Zweier et al.
who recently reported formation of NO in biological tissues
that was independent of NO synthase [38].
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Fig. 5. Hanes-Woolf plot of NO production catalysed by XOR in
the presence of inorganic nitrite and 300 WM NADH. Experiments
were carried out and analysed as described in the legend to Fig. 2.
Inset shows the Michaelis-Menten curve ¢tted to the data.
Fig. 4. Hanes-Woolf plot of NO production catalysed by XOR in
the presence of inorganic nitrate and 300 WM NADH. Experiments
were carried out and analysed as described in the legend to Fig. 2.
Inset shows the Michaelis-Menten curve ¢tted to the data.
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